Companies Dominating the In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Landscape
- DiaSorin S.p.A.,
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- American Laboratory Products Company, Ltd.
- (d/b/a ALPCO Diagnostics),
- Quidel Corporation,
- CerTest Biotec, S.L.,
- BUHLMANN Laboratories AG,
- BioSystems S.A., Inova Diagnostics, Inc. (Werfen), and others.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the in-vitro inflammatory bowel disease (IBD) diagnostic market that are included in our report are
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of in-vitro IBD diagnostic is assessed at USD 2.02 billion.
In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market size was over USD 1.93 billion in 2024 and is projected to reach USD 3.78 billion by 2037, growing at around 5.3% CAGR during the forecast period i.e., between 2025-2037.
North America industry is estimated to account for largest revenue share of 44% by 2037, North America industry is estimated to account for largest revenue share of 44% by 2037
The major players in the market are are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, and others.
